

Special Issue

Drug Targeting for CNS Disease, 2nd Edition

Message from the Guest Editors

Current treatment of CNS diseases is largely symptomatic, and it does not bring satisfactory therapeutic effects. Today, there is a crucial need to design strategies for new drug development based on a better understanding of the biochemical mechanisms underlying the pathological conditions and on molecular targeting of therapeutic molecules based thereupon. Experimental and clinical observations reveal that nonselective, multipotent drugs appear to be more effective. According to the most recent trends, we should apply therapeutic tools which will simultaneously affect various systems (dual targeting drugs, multitargeting drugs).

In this Special Issue, original papers and reviews on neurodegenerative diseases, mental diseases, addictions or cancer as well as molecular targets involved in these diseases are welcome. Covered topics include (but are not limited to) the search for new active compounds (medicines) along with pharmacological and pharmacokinetic evaluation. All preclinical (in vitro, ex vivo, and in vivo tests) as well as clinical studies for the prevention or treatment of CNS diseases are invited.

Guest Editors

Dr. Dorota Łażewska

Faculty of Pharmacy, Jagiellonian University Medical College in Kraków,
ul. Medyczna 9, 30-688 Kraków, Poland

Dr. Anna Stasiak

Department of Hormone Biochemistry, Faculty of Medicine, Medical
University of Lodz, Żeligowskiego 7/9 Str., 90-752 Lodz, Poland

Deadline for manuscript submissions

closed (10 January 2025)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/185555

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).